T-Therapeutics reloads with a $133M megaround for bispecifics

BioPharma DiveView source article

Part of story

T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.

Nov 5, 20262 sourcesCancer immunotherapy Cancer & Oncology Immunotherapy Venture capital funding Drug development Biotech startup Eli Lilly Autoimmune disease treatments

T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

Other sources for this story

Endpoints

T-Therapeutics reloads with a $133M megaround for bispecifics

Part of story

T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

Other sources for this story

T-Therapeutics secures $133M for cancer, autoimmune TCRs

T-Therapeutics reloads with a $133M megaround for bispecifics

Part of story

T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

Other sources for this story

T-Therapeutics secures $133M for cancer, autoimmune TCRs